Trial re-investment to build better research for better impact
Lancet
.
2019 Aug 24;394(10199):635-636.
doi: 10.1016/S0140-6736(19)31363-7.
Authors
Thomas A Fox
1
,
Gillian A Horne
2
,
Charles Craddock
3
,
Gordon Cook
3
,
Stephen O'Brien
4
,
Sonia Fox
5
,
Anna Hockaday
6
,
Graham Silk
7
,
Peter Hillmen
8
Affiliations
1
Department of Haematology, University College London, London, UK.
2
Beatson West of Scotland Cancer Centre, Glasgow, UK.
3
Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4
Northern Institute for Cancer Research, Newcastle University, Newcastle, UK.
5
Cancer Research UK Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham, UK.
6
Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
7
Cure Leukaemia, Birmingham, UK.
8
Department of Haematology, St James's University Hospital, Leeds, LS9 7TF, UK. Electronic address: peter.hillmen@nhs.net.
PMID:
31448733
DOI:
10.1016/S0140-6736(19)31363-7
No abstract available
Publication types
Letter
MeSH terms
Drug Approval / economics
Humans
Randomized Controlled Trials as Topic / economics*
Randomized Controlled Trials as Topic / statistics & numerical data
United Kingdom
Grants and funding
14030/LLR_/Blood Cancer UK/United Kingdom
15790/CRUK_/Cancer Research UK/United Kingdom
25447/CRUK_/Cancer Research UK/United Kingdom